Drs. Nate Pennell, Mary Pinder, and Jack West discuss the Biomarkers France trial of testing on a national scale for clinically relevant biomarkers in advanced non-small cell lung cancer (NSCLC).

[powerpress]

Dr. Greg Riely, from Memorial Sloan-Kettering, provides his perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.

[powerpress]

Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, reviews his thought process in recommending a repeat biopsy after progression for patients with advanced lung cancer.

[powerpress]

Dr. Sarah Goldberg from Yale Cancer Center describes which patients with advanced NSCLC she seeks molecular marker testing on.

[powerpress]

Dr. David Spigel, Sarah Cannon Cancer Center, gives his view on more widespread availability of new mutation tests.

[powerpress]

Dr. Heather Wakelee, from Stanford University, provides her perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.

[powerpress]

Dr. Greg Riely, from Memorial Sloan-Kettering, expresses his practice pattern for patients with advanced non-small cell lung cancer who would need a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.

[powerpress]

Dr. Karen Kelly, of the University of California, Davis, reviews her thought process in recommending a repeat biopsy after progression for patients with advanced lung cancer.

[powerpress]

Dr. Rosalyn Juergens, McMaster University, discusses the question of widespread availability of new mutation tests under the Canadian health care system.

[powerpress]

Dr. Sarah Goldberg from Yale Cancer Center describes which molecular markers she seeks for NSCLC patients.

[powerpress]